Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study

2018/11/08 by Jim Luijten, Marleen M. J. van Greevenbroek, Marleen M.J. van Greevenbroek +8 · 12 citations
Medicine · #Lipoproteins and Cardiovascular Health #Diabetes, Cardiovascular Risks, and Lipoproteins #HIV-related health complications and treatments

paper · doi:10.1016/j.atherosclerosis.2018.11.013

Cited by

• Coronary Artery Disease Risk and Lipidomic Profiles Are Similar in Hyperlipidemias With Family History and Population-Ascertained Hyperlipidemias. [europepmc]
• Incidence of type 2 diabetes in familial combined hyperlipidemia. [europepmc]
• Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor. [europepmc]
• Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson's, Martin's and Friedewald's equations. [europepmc]
• Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperine. [europepmc]
• Microwave-Assisted Synthesis, Biological Activity Evaluation, Molecular Docking, and ADMET Studies of Some Novel Pyrrolo [2,3- b ] Pyrrole Derivatives. [europepmc]
• Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. [europepmc]
• Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study. [europepmc]
• A novel mouse model of familial combined hyperlipidemia and atherosclerosis. [europepmc]
• Characterization and interactions between piperine and ezetimibe in their Anti-hyperlipidemic efficacy using Biopharmaceutics and Pharmacokinetics. [europepmc]
• Familial Combined Hyperlipidemia: Myth or Reality? [europepmc]
• Development and Validation of a New Nomogram for Predicting Medication Nonadherence Risk in a Chinese Hyperlipidemia Population. [europepmc]